ILLUMINA, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 108.6 USD | -0.46% |
|
-3.21% | -21.74% |
| 06-17 | RBC Cuts Price Target on Illumina to $249 From $253, Maintains Outperform Rating | MT |
| 06-11 | Illumina Inc. Announces Launch of DRAGEN v4.3 | CI |
Presenter SpeechEve Burstein (Analysts)Good morning, everyone. Thanks so much for joining us. ...
This article is reserved for subscribers To unlock the article, SUBSCRIBE!
Already a customer? Log In
Illumina, Inc. specializes in the development, manufacturing and marketing of integrated systems for the analysis of genetic variation and biological function. The group's products are for genomic research centers, pharmaceutical companies, university institutions, clinical research organizations, and biotechnology companies. Net sales break down by source of income as follows:
- product sales (84.1%): tools and instruments for sequencing, genotyping, genetic expression, etc.;
- sales of services (15.9%).
Net sales are distributed geographically as follows: the United States (52.4%), Americas (3.6%), Europe (25.3%), Asia/Pacific/Middle East/Africa (10.2%) and China/Taiwan/Hong Kong (8.5%).
Calendar
07/08/2024
- Q2 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
109.1
USD
Average target price
153.6
USD
Spread / Average Target
+40.82%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -21.74% | 17.37B | |
| +7.45% | 217B | |
| +10.83% | 188B | |
| +28.05% | 153B | |
| +30.98% | 112B | |
| -0.80% | 62.84B | |
| +14.05% | 52.35B | |
| +1.85% | 49.33B | |
| +1.02% | 35.4B | |
| +22.75% | 30.9B |
- Stock Market
- Equities
- ILMN Stock
- News Illumina, Inc.
- Transcript : Illumina, Inc. Presents at Bernstein?s 40th Annual Strategic Decisions Conference, May-29-2024 09
